Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:41:16.854Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:41:16.854Z.
Quote observation: 2026-10-06T15:40:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 95041c5b42fb2606cad9ef3462ba84fd1ad3ee370422abc55eb90f4681bfa3ac
FORWARD PE RATIO
N/A
CDT Equity Inc.
Market Cap
$678164.00
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| CDT Equity Inc. (CDT) | $678164.00 | N/A |
| HCW Biologics Inc. (HCWB)vs › | $549273.00 | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $834083.00 | N/A |
| Bone Biologics Corporation (BBLG)vs › | $851060.00 | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $856468.00 | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $873967.00 | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $374618.00 | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.04M | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.07M | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
